Abstract: The present disclosure provides an ophthalmic formulation comprising one or more pharmaceutically acceptable excipients; a pharmaceutically active compound that is capable of reducing the amount or deleterious actions of autoantibodies on the ocular surface, such as IgG; In particular, the present disclosure provides an ophthalmic formulation where the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory, infectious and immunological ocular surface or intraocular disease that can cause symptoms of ocular discomfort, keratitis, dry eye disease, symblepheron formation, fornix foreshortening, eyelid margin/conjunctival keratinization, subconjunctival fibrosis, retinal gliosis and glaucoma.

Abstract: A system for securing a secret word during a read of the secret word from a read-only memory (ROM) is disclosed. The system includes a memory controller coupled to the ROM and a random number generator coupled to the memory controller. The random number generator is configured to generate a random number. The system further includes a number shuffler coupled to the random number generator and the memory controller. The number shuffler is configured to generate a bit read order based on the random number and the memory controller is configured to read bits of the secret word from the ROM according to the bit read order.

Abstract: A display device for illuminating a packaged beverage includes a panel having a front end opposite a rear end. The panel further includes a top surface on which a packaged beverage may be placed, and the top surface has transparent portions. A light source is arranged within the panel for illuminating the packaged beverage arranged on the top surface of the panel. The display device further includes an end cap having a front wall arranged at the front end of the panel.

Abstract: An application operating on a portable computing device that generates a suggested hypothesis of at least one of: a diagnosis, a treatment, and subsequent medical investigation. The application receives quantified subfactors, collectively defining factors, for each patient. Subfactors of the medical condition are related to the history, symptoms, signs, tests, and responses to the treatment. The application determines an odds ratio for each factor regarding each hypothesized medical condition as well as an associated prevalence. The application can also determine a respective sensitivity and specificity. Posterior probability distribution, such as using Bayesian statistics, can be applied using odds ratios, prevalence, sensitivity specificity, and the associated correlations to determine the suggested hypothesis of the diagnosis, treatment, and any next tests.

Abstract: A kit and methods for diagnosing and treating a dry eye disease or other ocular disease are provided, which include determining whether a reduced level of a histatin is present in a biological fluid sample from a subject.

Abstract: The present invention provides an ophthalmic formulation consisting essentially of one or more pharmaceutically acceptable excipients; a pharmaceutically active compound that is capable of reducing the amount of inflammatory neutrophil product on the ocular surface; and optionally a second pharmaceutically active compound selected from the group consisting of a steroid, an anti-inflammatory agent, a mucolytic agent and a combination thereof. In particular, the present invention provides an ophthalmic formulation where the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory and immunological ocular surface disease that can cause symptoms of ocular discomfort, mucocellular aggregates/debris in tear film, symblepheron formation, fornix foreshortening, eyelid margin/conjunctival keratinization, corneal neovascularization/pannus, subconjunctival fibrosis, and herpetic eye disease.

Abstract: A secure read-only-memory (ROM) code patching system includes a processor that is configured to generate first partial cryptographic data based on a ROM patch and a set of secret bits, and authenticate the ROM patch based on a match between the first partial cryptographic data and reference partial cryptographic data of the ROM patch. Upon the authentication of the ROM patch, the processor is further configured to generate an address associated with a set of ROM instructions of a ROM code. Based on a match between the generated address and a ROM patch address of the ROM patch, the processor is further configured to execute a set of patch instructions of the ROM patch that is successfully authenticated instead of the set of ROM instructions, thereby securely patching the ROM code.

Abstract: A system to facilitate communication of a critical signal between functional circuitries of a system-on-chip utilizes a dynamic pattern to securely communicate the critical signal. The system includes selection and comparison circuits. The selection circuit is configured to select and output a set of dynamic pattern bits or a set of fixed reference bits, based on a logic state of the critical signal that is received from one functional circuitry. The comparison circuit is configured to output an output signal based on the set of dynamic pattern bits, and a set of intermediate bits that is derived from the set of dynamic pattern bits or the set of fixed reference bits. The output signal is provided to the other functional circuitry when a logic state of the output signal matches the logic state of the critical signal, thereby securely communicating the critical signal to the other functional circuitry.

Abstract: Communications software that minimizes recipient distractions from receiving messages receives, at an application running on a computing device of an application user referred to as a sender, input for a message to a recipient address. A notice of the message is received from the application to the recipient address at a distraction free messaging (DFM) server. The DFM server querying settings established by a recipient linked to the recipient address to determine a delivery time for the message. The DFM server conveys over a network the delivery time to the application running on the computing device of the sender. At the delivery time, the DFM server delivering the message to the recipient address enabling the recipient to view the message as a delivered message, wherein prior to the delivery time the recipient is permitted to preview the message via a distraction free message application operating in a pre-delivery mode.

Abstract: A system for securing a secret word during a read of the secret word from a read-only memory (ROM) is disclosed. The system includes a memory controller coupled to the ROM and a random number generator coupled to the memory controller. The random number generator is configured to generate a random number. The system further includes a number shuffler coupled to the random number generator and the memory controller. The number shuffler is configured to generate a bit read order based on the random number and the memory controller is configured to read bits of the secret word from the ROM according to the bit read order.

Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Abstract: A cooling system having a cooling chamber including a surface defining one or more openings. A surface is configured to hold at least one container. An access door provides access to the cooling chamber. A refrigeration system is configured to cool the cooling chamber by forcing cool airflow through the one or more openings in the surface. The airflow through each of the one or more openings may be similar.

Abstract: The present invention provides an ophthalmic formulation consisting essentially of one or more pharmaceutically acceptable excipients; a pharmaceutically active compound that is capable of reducing the amount of inflammatory neutrophil product on the ocular surface; and optionally a second pharmaceutically active compound selected from the group consisting of a steroid, an anti-inflammatory agent, a mucolytic agent and a combination thereof. In particular, the present invention provides an ophthalmic formulation where the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory and immunological ocular surface disease that can cause symptoms of ocular discomfort, mucocellular aggregates/debris in tear film, symblepheron formation, fornix foreshortening, eyelid margin/conjunctival keratinization, corneal neovascularization/pannus, subconjunctival fibrosis, and herpetic eye disease.

Abstract: A process for the recovery of polymer-grade (meth)acrylic acid, in the absence of organic solvent, from a gaseous reaction mixture comprising (meth)acrylic acid obtained by gas-phase oxidation of a precursor of the (meth)acrylic acid, the process carried out in a plant comprising at least one dehydration column and one finishing column, being characterized by the presence of at least one chemical treatment agent targeted at reducing the content of residual aldehydes. (Meth)acrylic acid obtained according to the invention meets criteria of high quality allowing it to be used in the manufacture of acrylic polymers, in particular for superabsorbents. This grade is also known as glacial acrylic acid GAA.

Abstract: Systems and method for idle loop detection and control are disclosed. A processor operates in operating modes including an active mode and a disabled mode, and an interconnect bus is coupled between the processor and one or more additional electronic circuits. Logic within the processor is coupled to snoop the interconnect bus, and the logic is programmed to detect a new idle loop based upon repeated instructions on the interconnect bus and to place the processor in the disabled mode based upon execution of the new idle loop, which represents a previously unknown idle loop for the processor. Further, the logic can be programmed to store state data for the processor when the new idle loop is detected, and the logic can also be programmed to place the processor in the active mode based upon detection of a wakeup event for the new idle loop on the interconnect bus.

Abstract: A semiconductor device including scan configuration circuitry that reconfigures latches of the device into a scan chain in response to assertion of a scan enable control signal, and scan control circuitry including delay circuitry, scan enable circuitry, evaluation circuitry, and scan reset circuitry. The scan reset circuitry keeps each of the secure latches in a predetermined reset state until assertion of both an evaluation signal and a scan mode signal. The delay circuitry includes N series-coupled flip-flops selected from different cell libraries detecting assertion of the scan mode signal and asserting a delay output signal only after N transitions of a test clock. The scan enable circuitry asserts the scan enable control signal when a scan enable command signal and the delay output signal are both asserted. The evaluation circuitry asserts the evaluation signal only when a collective state of the delay circuitry has achieved a predetermined state.

Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Abstract: Systems and methods include, responsive to a Wi-Fi client device providing a password for a zone of a Wi-Fi network, determining a status of the Wi-Fi client device; when the status is unknown, placing the client device in a holding area associated with the zone, wherein the client device is connected to the Wi-Fi network while in the holding area and has restricted access that is less than full access to the zone in an allowed zone; responsive to placing the client device in the holding area, causing a notification to an administrator that the client device is in the holding area; and with the client device in the holding area, one of moving the Wi-Fi client device to the allowed area, moving the client device to a rejected area for the zone, and leaving the client device in the holding zone, based on any input or lack thereof.

Abstract: The present invention concerns a method of decarbonating a gas stream containing from 15% to 60% carbon dioxide, by passage of the said gas stream over a zeolitic agglomerate comprising at least one binder and at at least one zeolite, and having a mesoporous volume of between 0.02 cm3·g?1 and 0.15 cm3·g?1 and a mesoporous volume fraction of between 0.1 and 0.5, preferably between 0.15 and 0.45.